Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars

Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars


The Lilly Biotechnology Center in San Diego, California, on March 1, 2023.

Mike Blake | Reuters

Eli Lilly on Thursday reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs soared but it saw lower realized prices.

The figures were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors. Eli Lilly had slashed its 2024 revenue guidance, as it said demand for its weight loss and diabetes drugs would not meet its lofty expectations.

The company’s earnings topped Wall Street estimates, but sales fell just short.

Here’s what Eli Lilly reported for the period compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

  • Earnings per share: $5.32 adjusted vs. $4.95 expected
  • Revenue: $13.53 billion vs. $13.57 billion expected

This story is developing. Please check back for updates.



Source

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Health

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of […]

Read More
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
Health

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, a landmark decision that health experts […]

Read More
UnitedHealth Group commits to improvements after independent audit, patient backlash
Health

UnitedHealth Group commits to improvements after independent audit, patient backlash

UnitedHealthcare sign is displayed at its office building in Minnetonka, Minnesota, U.S., Dec. 11, 2025. Tim Evans | Reuters UnitedHealth Group on Friday released the first results from a sprawling independent audit of its business practices and committed to a wide range of steps to track and implement improvements in three specific areas. The health-care […]

Read More